Autoimmune disease and pregnancy

SEATTLE – For many aspiring mothers with autoimmune disease, pregnancy can be daunting and full of unknowns. In some cases, those suffering from specific autoimmune conditions have chosen to forego pregnancy altogether due to concerns about their disease treatments and adverse pregnancy outcomes.

In a just-published study in the journal Lancet eClinical Health, researchers at the Institute for Systems Biology (ISB) and Providence showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease. The findings reinforce that there isn’t a one-size-fits-all approach, and provides important new avenues for further investigation.

“Research has been advancing rapidly. If you are living with an autoimmune disease and are currently pregnant or thinking of having a baby, I highly recommend you talk to your autoimmune disease specialist about pregnancy and the many factors to consider about your treatment and other important decisions,” said Philip Mease, MD, a Providence rheumatology expert and part of the study team.

The research team examined the electronic health records of more than 365,000 pregnant individuals over a 10-year period, including more than 5,700 patients who had at least one of 12 autoimmune disorders: Psoriasis, inflammatory bowel disease, rheumatoid arthritis, spondyloarthritis, multiple sclerosis, systemic lupus erythematosus, psoriatic arthritis, antiphospholipid syndrome, Sjögren's syndrome, vasculitides, sarcoidosis, and systemic sclerosis.

The researchers accounted for a large number of pregnancy and maternal characteristics associated with preterm birth, as well as many other medical conditions, such as hypertension and diabetes. Their results provide an intricate relationship between autoimmune disease and pregnancy outcomes. 

Notably, for pregnancy after 20 weeks of gestational age:

• In patients with autoimmune disease, the presence of other medical conditions is an important factor in risk for preterm birth, small for gestational age and low birth weight.
• Adjusting for other medical conditions reinforced that patients with lupus have higher risk for adverse pregnancy outcomes.
• Unexpectedly, after adjusting for comorbidities, patients with rheumatoid arthritis or inflammatory bowel disease did not show significantly higher risk for adverse pregnancy outcomes.

“A blanket statement that ‘autoimmune disease is high risk for pregnancy’ isn’t sufficient. Each type of autoimmune disease is different, each person has their own medical history, and risk may change over the course of pregnancy. This study highlights the importance of taking comorbidities into consideration,” said ISB Associate Professor Jennifer Hadlock, MD, who led the study. “It was unexpected to see that in pregnancy after 20 weeks of gestational age, rheumatoid arthritis and inflammatory bowel disease were not necessarily associated with increased risk for preterm birth. This raises new questions about the interconnections between comorbidities and autoimmune disease.”

There is a significant need for prospective studies that look across the duration of  pregnancy and include more details on the severity and management of both autoimmune disease and other co-occurring medical conditions.

“These results can help reshape discussions surrounding autoimmune disease and pregnancy, and bring fresh perspective to a traditionally understudied area in research,” Hadlock said.

About ISB
Institute for Systems Biology (ISB) is a collaborative and cross-disciplinary non-profit biomedical research organization based in Seattle. We focus on some of the most pressing issues in human health, including aging, brain health, cancer, COVID-19, as well as many infectious diseases. Our science is translational, and we champion sound scientific research that results in real-world clinical impacts. ISB is an affiliate of Providence, one of the largest not-for-profit health care systems in the United States. Follow us online at www.isbscience.org, and on YouTube, Facebook, LinkedIn, Twitter and Instagram.